New COVID-19 diagnostic platform more efficient than commercial PCR test kits

Novel method detects asymptomatic cases with more than 95% sensitivity

05-Feb-2021 - Cima Universidad de Navarra researchers have developed a large-scale, highly sensitive COVID-19 diagnostic platform more efficient than the commercial PCR test kits currently available. It consists of a ribonucleic acid (RNA) extraction method which allows large quantities of samples to be ...

Digital Diagnostics Startup and BGI Group Collaborate to Offer Coronavirus Testing in Europe

03-Feb-2020 - Ares Genetics GmbH, a Curetis Group company, and the Chinese genomics company BGI Group announced that the companies will collaborate in making molecular testing for the new coronavirus 2019-nCoV available in Europe. 2019-nCoV is a new coronavirus variant that has not been previously identified ...

QIAGEN achieves Personalized Healthcare milestone with U.S. approval of companion diagnostic for colorectal cancer

11-Jul-2012 - QIAGEN N.V. announced it has received U.S. Food and Drug Administration (FDA) approval to market the therascreen® KRAS RGQ PCR Kit (therascreen KRAS test) to provide guidance on the use of Erbitux® (cetuximab) as a treatment in patients with metastatic colorectal cancer. The U.S. FDA approval of ...

QIAGEN Tests Clinically Verified for the Monitoring of Swine Flu

German Bernhard Nocht Institute Unequivocally Detects Infections with the H1N1 Strain Using the artus Influenza Test

07-May-2009 - Analyses performed by the German Bernhard Nocht Institute for Tropical Medicine have proven that the influenza A / H1N1 virus can be unequivocally detected using a screening test developed by QIAGEN. The company's artus Influenza LC RT PCR Kit was successfully used to screen a female patient who ...

QIAGEN and Institute for Animal Health Enter Partnership in Bluetongue Testing

10-Nov-2008 - QIAGEN N.V. has announced that it has entered into a worldwide exclusive partnership with the Institute for Animal Health (IAH), a research and diagnostics institution for infectious diseases of farm animals. Pursuant to the agreement QIAGEN has licensed a novel molecular assay design for ...

BIOTECON Diagnostics signs license agreement with Applera Corporation

26-May-2008 - Applera and BIOTECON Diagnostics (BCD) announced a non-exclusive, worldwide license agreement relating to PCR technology for Food Testing Applications and Genetically-Modified Organism (GMO) Testing Applications: BIOTECON Diagnostics has acquired important rights with the PCR licence. In the ...

Institut Pasteur Successfully Evaluates QIAGEN's Avian Flu/H5 Assay

14-Mar-2006 - QIAGEN N.V. announced that the Institut Pasteur in France successfully evaluated QIAGEN's artus® Influenza/H5 LC RT-PCR detection kit. The evaluation procedures of the Institut Pasteur included 18 different human influenza viruses, including 16 "seasonal" strains and two cases of human H5N1, and ...